NCT03575780View on ClinicalTrials.gov

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 7, 2018

Primary Completion Date

April 25, 2019

Study Completion Date

October 10, 2019

Conditions
Actinic Keratoses
Interventions
DRUG

KX2-391 Ointment 1%

The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.

Trial Locations (1)

07410

TKL Research, Fair Lawn

Sponsors

Lead Sponsor

Athenex, Inc.
All Listed Sponsors
collaborator

TKL Research, Inc.

INDUSTRY

lead

Athenex, Inc.

INDUSTRY